Dante J Pieramici, M.D., on changes to Susvimo port delivery system, ASRS 2024 скачать в хорошем качестве

Dante J Pieramici, M.D., on changes to Susvimo port delivery system, ASRS 2024

In this video Dante J. Pieramici, M.D., summarizes his presentation at the American Society of Retinal Specialists meeting last week in Stockholm, Sweden about changes made to the Susvimo port delivery system. Genentech pulled Susviomo off the market in October 2022 after the valve-like septum that receives the needle used to refill the device with ranibizumab became dislodged in 5% of patients. Pieramici, a Genentech consultant who is co-director of the California Retina Research Foundation and a partner of California Retina Consultants, said the geometry of the septum has been altered and the glueing procedure changed. In addition, the needle has been modified with a silicone lubricant. Pieramici said that in vitro testing of the new version of the port delivery system showed no failures in a model that was the equivalent to Susvimo being in a person's eye for 30 years. In vitro testing of the prior version showed 50% of the implants failed after 10 years, according to Pieramici, The changes to Susvimo mean "patients and physicians can be comfortable that this septum dislodgment is not going to occur in the future. They have solved the problem," Pieramici said,